Chemical genomics: Probing protein function using small molecules

American Journal of PharmacoGenomics

Volumn 4, Issue 5, 2004, Pages 313-320

  Wagner, Bridget K ^a   Haggarty, Stephen J ^a   Clemons, Paul A ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFECTIVE AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DNA; GELDANAMYCIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 90; IMATINIB; PROSTACYCLIN; PROSTACYCLIN SYNTHASE; PROSTAGLANDIN D; PROSTAGLANDIN E; PROSTAGLANDIN F; PROSTAGLANDIN H2; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RADICICOL; RNA; THROMBOXANE A2; THROMBOXANE SYNTHASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; CELL TYPE; CHEMICAL GENOMICS; CHRONIC MYELOID LEUKEMIA; DNA MICROARRAY; ENZYME INHIBITION; GENE EXPRESSION; GENOMICS; HUMAN; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALS; BENZOQUINONES; COMBINATORIAL CHEMISTRY TECHNIQUES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG DESIGN; GENOMICS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; ISOENZYMES; LACTAMS, MACROCYCLIC; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEINS; QUINONES;

ANIMALIA; MAMMALIA;

EID: 7644243551     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200404050-00004     Document Type: Review

References (44)

1. Dudgeon RE. Lectures on the theory and practice of homeopathy. Manchester: H. Turner, 1853
2. National Institute for Health Care Management. Changing patterns of pharmaceutical innovation [online]. Available from URL: http://www.nihcm.org/ innovations.pdf [Accessed 2004 Jul 27]
3. Strogatz SH. Exploring complex networks. Nature 2001; 410 (6825): 268-76
4. Jeong H, Tombor B, Albert R, et al. The large-scale organization of metabolic networks. Nature 2000; 407 (6804): 651-4
5. Wolf YI, Karev G, Koonin EV. Scale-free networks in biology: new insights into the fundamentals of evolution? Bioessays 2002; 24 (2): 105-9
6. Luscombe NM, Qian J, Zhang Z, et al. The dominance of the population by a selected few: power-law behaviour applies to a wide variety of genomic properties. Genome Biol 2002; 3 (8): RESEARCH0040
7. Nestler EJ, Hyman SE, Malenka RC. Molecular neuropharmacology: a foundation for clinical neuroscience. New York: McGraw-Hill Inc., 2001
8. Basbaum AI, Woolf CJ. Pain. Curr Biol 1999; 9 (12): R429-31
9. Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001; 108 (1): 7-13
10. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104 (5): 413-21
11. Sinicrope FA, Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev 2004; 23 (1-2): 63-75
12. Fife RS, Stott B, Carr RE. Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro. Cancer Biol Ther 2004; 3 (2): 228-32
13. Ramalingam S, Belani CP. Cyclooxygenase-2 inhibitors in lung cancer. Clin Lung Cancer 2004; 5 (4): 245-53
14. Subbaramaiah K, Bulic P, Lin Y, et al. Development and use of a gene promoter-based screen to identify novel inhibitors of cyclooxygenase-2 transcription. J Biomol Screen 2001; 6 (2): 101-10
15. Stegmaier K, Ross KN, Colavito SA, et al. Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation. Nat Genet 2004; 36 (3): 257-63
16. Grosser T, Yusuff S, Cheskis E, et al. Developmental expression of functional cyclooxygenases in zebrafish. Proc Natl Acad Sci U S A 2002; 99 (12): 8418-23
17. Whitesell L, Mimnaugh EG, De Costa B, et al. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 1994; 91(18): 8324-8
18. Sharma SV, Agatsuma T, Nakano H. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene 1998; 16 (20): 2639-45
19. Stebbins CE, Russo AA, Schneider C, et al. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997; 89 (2): 239-50
20. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002; 8 (4 Suppl.): S55-61
21. Roe SM, Prodromou C, O'Brien R, et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 1999; 42 (2): 260-6
22. Sreedhar AS, Soti C, Csermely P. Inhibition of Hsp90: a new strategy for inhibiting protein kinases. Biochim Biophys Acta 2004; 1697 (1-2): 233-42
23. Workman P. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. Cancer Chemother Pharmacol 2003; 52 Suppl. 1: S45-56
24. Basso AD, Solit DB, Munster PN, et al. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002; 21 (8): 1159-66
25. Hondermarck H, Dolle L, El Yazidi-Belkoura I, et al. Functional proteomics of breast cancer for signal pathway profiling and target discovery. J Mammary Gland Biol Neoplasia 2002; 7 (4): 395-405
26. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344 (14): 1031-7
27. Gorre ME, Ellwood-Yen K, Chiosis G, et al. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002; 100 (8): 3041-4
28. Piper PW, Millson SH, Mollapour M, et al. Sensitivity to Hsp90-targeting drugs can arise with mutation to the Hsp90 chaperone; cochaperones and plasma membrane ATP-binding-cassette transporters of yeast. Eur J Biochem 2003; 270: 4689-95
29. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425 (6956): 407-10
30. Neckers L, Lee YS. Cancer: the rules of attraction. Nature 2003; 425 (6956): 357-9
31. Butte AJ, Dzau VJ, Glueck SB. Further defining housekeeping, or "maintenance", genes focus on "a compendium of gene expression in normal human tissues". Physiol Genomics 2001; 7 (2): 95-6
32. Warrington JA, Nair A, Mahadevappa M, et al. Comparison of human adult and fetal expression and identification of 535 housekeeping/maintenance genes. Physiol Genomics 2000; 2 (3): 143-7
33. Zhang L, Li WH. Mammalian housekeeping genes evolve more slowly than tissue-specific genes. Mol Biol Evol 2004; 21 (2): 236-9
34. Blanquicett C, Johnson MR, Heslin M, et al. Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic gene expression studies. Anal Biochem 2002; 303 (2): 209-14
35. Chi JT, Chang HY, Haraldsen G, et al. Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci U S A 2003; 100 (19): 10623-8
36. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999: 286(5439): 531-7
37. Ramaswamy S, Tamayo P, Rifkin R, et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A 2001; 98 (26): 15149-54
38. Giaever G, Shoemaker DD, Jones TW, et al. Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat Genet 1999; 21 (3): 278-83
39. Lum PY, Armour CD, Stepaniants SB, et al. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 2004; 116(1): 121-37
40. Haggarty SJ, Clemons PA, Schreiber SL. Chemical genomic profiling of biological networks using graph theory and combinations of small molecule perturbations. J Am Chem Soc 2003; 125 (35): 10543-5
41. Parsons AB, Brost RL, Ding H, et al. Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. Nat Biotechnol 2004; 22(1): 62-9
42. Dolma S, Lessnick SL, Hahn WC, et al. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 2003; 3 (3): 285-96
43. Stein RL. High-throughput screening in academia: the Harvard experience. J Biomol Screen 2003; 8 (6): 615-9
44. Brown ED. Screening in academe: a perspective on implementation of university-based small molecule screening. J Biomol Screen 2003; 8 (4): 377-9